Health News Releases

  • Today March 21
September 14, 2022 13:55
GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints
September 13, 2022 16:40
Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors
Rhizen Pharmaceuticals AG (Rhizen), a Swiss based privately held, clinical-stage biopharmaceutical company announced today that it is presenting data from an ongoing Phase 2 trial of Tenalisib in loca
September 13, 2022 11:15
PDC*line Pharma Presents First Clinical Results From Phase I/II trial With PDC*lung01 at ESMO 2022
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the first results of PDC-LUNG-101 phase I/II clinica
September 08, 2022 16:50
Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care
Merck, a leading science and technology company, today announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly
September 08, 2022 16:50
Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients
Merck, a leading science and technology company, today announced the latest research from the Company’s oncology portfolio and pipeline to be presented at this year’s European Society of Medical Oncol
September 07, 2022 14:30
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Públi
September 07, 2022 10:50
Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG
Lysando AG - market leader in the field of antimicrobial proteins - is pleased to announce that Fabian Geldmacher, M.D., has joined the team as Director Strategy & Business Development in June. Dr. Ge
September 06, 2022 16:00
GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress
Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022. These include on-
September 06, 2022 10:30
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Today, Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of nintedanib in children and adolescents between 6 and 17
Discovery process of high-grade serous ovarian cancer (HGSOC) biomarker candidates
September 06, 2022 10:21
Research Results of New Biomarker for Ovarian Cancer Diagnosis through Bertis’ Platform Published in Journal of Proteome Research
Bertis, a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced that the research results of their search for protein biomarkers for early
September 05, 2022 16:45
CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 20
September 02, 2022 16:55
U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults
The U.S. Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psoriasis (GPP) flares in adults, Boehringer Ingelheim anno
September 02, 2022 15:30
Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, sh
September 01, 2022 17:10
Aster Guardians Global Nursing Award 2023 Worth US $250,000 is Now Open for Nominations from Nurses Worldwide
In its continued efforts to recognize the contribution of nurses to mankind and to the healthcare community, Aster DM Healthcare has announced the next edition of the Aster Guardians Global Nursing Aw
HK inno.N CI
September 01, 2022 14:19
GICELL to Collaborate with HK inno.N on Research and Development for next-generation CAR-NK Therapy
GICELL announced research and development collaboration for allogeneic CAR-NK candidates with HK inno.N on August 29th, 2022. The companies plan to advance the development of numerous CAR-NK therap
August 31, 2022 09:00
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the
August 30, 2022 18:00
Aleph Farms Joins AIM for Climate as Newest Innovation Sprint Partner to Advance Cellular Agriculture
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that it has been officially recognized by the Agriculture Innovatio
August 29, 2022 14:45
Covetrus Names Margie B. Pritchard General Counsel
Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben
August 29, 2022 13:30
The Polypill Reduces Cardiovascular Mortality by 33% in Patients Treated After Myocardial Infarction
The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardio
August 26, 2022 14:00
PCI Pharma Services Opens New England Center of Excellence to Bring Global Clinical Supply Capabilities to New England
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the opening of its Clinical Services Center of Excellence in Bridgewater, MA, th
August 25, 2022 15:40
Galderma Delivers Strong H1 2022 Results and Continued Innovation Across Its Leading Dermatology Portfolio
Galderma: Continued strong commercial and financial performance in a resilient market · Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year o
August 25, 2022 13:30
Biocytogen Expands Partnership with Merck
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice™ platform. Under the terms of the agreement, Merc
August 25, 2022 10:30
AdvanCell Closes A$18M Series B Funding Led by Morningside
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Serie
August 24, 2022 16:20
Morinaga Milk Obtains FDA GRAS Notification for its Probiotic
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium longum subsp. infantis M-63 has received FDA GRAS (Ge
August 24, 2022 14:40
Frazier Life Sciences Adds Senior R&D Leader to Team
Frazier Life Sciences announced the addition of Annette Doherty, Ph.D., OBE, FRSC as a Senior Advisor. She has 35 years of international experience as a chemist and leader of pharmaceutical research a
Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
August 23, 2022 17:00
Miracor Medical Announces FDA IDE Approval For PiCSO® Pivotal Study
Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled
August 23, 2022 16:50
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment
August 23, 2022 16:20
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
Takeda (TSE:4502/NYSE:TAK) today announced the company’s dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and F
August 23, 2022 14:00
Medisca Unveils New Brand Identity and Corporate Positioning as Partners in Wellness
After three successful decades of redefining, shaping, and informing the pharmaceutical compounding industry standard, Medisca is proud to unveil a new global brand identity and corporate positioning
August 23, 2022 11:35
Solasia Announces Launch of Darvias® in Japan
Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (S
August 22, 2022 16:30
VFMCRP announces U.S. Court upholds validity of Velphoro® patent
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 whi
August 19, 2022 14:50
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Produ
August 18, 2022 16:40
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituxim
August 10, 2022 11:10
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22
August 05, 2022 11:10
GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution
Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a nov
August 04, 2022 17:25
ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial
ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States. Immu
August 04, 2022 15:45
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in a
August 04, 2022 14:40
SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination f
August 03, 2022 11:55
Adalvo Acquires Its First Branded Product, Onsolis®
The global pharmaceutical company Adalvo today announced the acquisition of its first branded product, Onsolis® after concluding a deal with a reputable US based specialty pharmaceutical Company, that
August 03, 2022 11:05
Wilhelm von Haller is Chief Financial Officer of Lysando AG
Lysando AG - market leader in the field of antimicrobial proteins - is pleased to announce that Wilhelm von Haller has joined the team as Chief Financial Officer this March. Baron von Haller is an exp
August 02, 2022 17:05
Finalization of Vifor Pharma acquisition
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Limited (ASX: CSL; USOTC:CSLLY) is pleased to announce it has now received all necessary regulatory clearances for the acquisition
August 02, 2022 11:30
Graminex®, L.L.C. Completes Clinical Trial with Graminex® Flower Pollen Extract Focusing on Women’s Urinary Incontinence with Positive Results.
Graminex®, L.L.C. is pleased to announce it has completed a clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health with positive results. This study wa
July 29, 2022 14:00
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance.
July 29, 2022 11:20
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
Organon (NYSE: OGN), a global women’s healthcare company, and Cirqle Biomedical today announced they have entered into a research collaboration and exclusive license agreement for a novel investigatio
July 28, 2022 11:10
PCI Pharma Services Announces Multi-Million Dollar Expansion to UK Manufacturing Facility to Meet Growing Demand for Global High Potent Manufacturing Services Supporting Oncology Treatments
PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced a significant expansion of its world-class facility in Tredegar, Wales, UK, desi
July 26, 2022 15:00
EssilorLuxottica Modernizes Order Processing With Boomi’s Intelligent Integration Platform
Boomi™, the intelligent connectivity and automation leader, today announced that EssilorLuxottica, a global leader in the eyewear market, has implemented Boomi's integration platform as a service (iPa
July 25, 2022 16:23
Increased Adoption of Imaging Technology To Detect And Monitor Ailment Severity Is Accelerating The Mobile Imaging Services Industry In Asia Pacific: Scrutinized Report By Fact.MR
The mobile imaging services market is predicted to account for USD 2.7 billion in 2032, up from USD 1.9 billion in 2022, advancing at a CAGR of 3.9% during the forecast period (2022-2032). The incr
July 22, 2022 16:10
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda (TSE:4502/NYSE:TAK) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombina
July 22, 2022 13:45
Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma
Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for the treatment of peripheral nerve injuries (PNI),
Digital Industries at Siemens Korea awarded students at the 9th Smart NC Contest Award Ceremony held
July 22, 2022 09:55
Siemens Korea Digital Industries Holds 9th Smart NC Contest Award Ceremony
Digital Industries (DI) of Siemens Korea (Siemens Ltd. Seoul·SLS) held the 9th Smart Numerical Control (NC) Contest Award Ceremony on July 21 at the Korea Digital Enterprise Experience Center (KDEXc)
25 per page50 per page75 per page100 per page